Astrazeneca plc ADR (NASDAQ:AZN) shares, rose in value, with the stock price up by 5.38% to the previous day’s close as strong demand from buyers drove the stock to $75.03.
Actively observing the price movement in the last trading, the stock closed the session at $71.20. The PE ratio was 36.98 over 12-month period. Referring to stock’s 52-week performance, its high was $76.56, and the low was $60.47. On the whole, AZN has fluctuated by 13.12% over the past month.
The company’s Forward Dividend Ratio is 1.45, with its dividend yield at 1.93%.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 50.95B, with a low estimate of 11.7B and a high estimate of 12.07B. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 11.83B.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AZN’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 2.80, with the price of AZN currently trading nearly 9.61% and 12.62% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 81.68, while the 7-day volatility ratio is showing 1.33% which for the 30-day chart, stands at 1.33%. Furthermore, Astrazeneca plc ADR (AZN)’s beta value is 0.51, and its average true range (ATR) is 1.26.
A comparison of Astrazeneca plc ADR (AZN) with its peers suggests the former has fared considerably weaker in the market. AZN showed an intraday change of 5.38% in last session, and over the past year, it shrunk by -0.83%%.
Data on historical trading for Astrazeneca plc ADR (NASDAQ:AZN) indicates that the trading volumes over the past 3 months, they’ve averaged 6.19 million. According to company’s latest data on outstanding shares, there are 3.10 billion shares outstanding.
Nearly 0.03% of Astrazeneca plc ADR’s shares belong to company insiders and institutional investors own 16.00% of the company’s shares. The stock has risen by 11.40% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AZN stock heading into the next quarter.
